Abstract 5113
Background
BioRAIDs is a supervised longitudinal collection of tumor and blood together with clinical outcome data in 419 primary cervical cancer patients from 7 European countries (NCT02428842).
Methods
Molecular analysis [Next Generation Sequencing (NGS) at SeqOmics (Hungary) & Reverse Phase Protein array (RPPA) at Institut Curie] was performed on quality-controlled primary tumor samples in 295 patients (70%) who subsequently had received primary radio chemotherapy (RCT). Integrative bioinformatics analyses were performed to identify pathway activations suggesting the need for additional/different therapies.
Results
NGS demonstrated driver Tyrosine Kinase Receptor/ PI3 kinase (TKR/PI3K) pathway mutations in 27%; TKR/PI3K + epigenetic pathway alterations (MLL2, MLL3) in 32 % and epigenetic alterations alone in 13% of patients. At a median follow up of 19 months [2-38], tumors for which no mutations in relevant genes from the TKR/PI3K pathways nor alterations in genes involved in epigenetic signaling appeared to be associated with a significantly better prognostic profile: HR = 2.4 [95% CI: 1.1 – 5.2]. RPPA analysis was carried out separating patients in 3 subgroups according to signaling pathway activation [EMT (epithelial mesenchymal transition), DNA damage and MAPK/PI3K], none of which was associated with bad prognosis.
Conclusions
The high frequency of epigenetic alterations with or without TKR/PI3K pathway mutations, suggests that epigenetically acting drugs (VorinostatR) may be relevant for patients whose tumors have genetic mutations of significance in epigenetically acting enzymes. Relevance of copy number alterations and of other frequently mutated genes (CSMD3, SYNE1), needs to be integrated and cross validated in a larger complementary dataset.
Clinical trial identification
NCT02428842.
Legal entity responsible for the study
Institut Curie.
Funding
This project has received founding from the European Union’s Seventh Program for research, technological development and demonstration under grant agreement No 304810.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract